The formulation science behind subcutaneous durvalumab

AstraZeneca’s subcutaneous durvalumab formulation centres on a 120 mg/mL high-concentration liquid preparation co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), histidine buffer at pH 5.5–6.5, sucrose as a stabiliser, and polysorbate 80 as a surfactant. The combination solves two fundamental challenges of SC delivery for large monoclonal antibodies: viscosity management and subcutaneous bioavailability.

At concentrations above 100 mg/mL, IgG1 antibodies like durvalumab typically exhibit high viscosity that prevents injection through standard SC needles. According to published pharmaceutical sciences research, the target viscosity for auto-injector compatibility is below 20 cP. AstraZeneca’s formulation addresses this through a combination of histidine-HCl buffer — which reduces viscosity compared with acetate buffer for IgG1 antibodies — and viscosity-reducing excipients including L-arginine and sodium chloride combinations, which can reduce viscosity by 30–40% in concentrated IgG formulations at 100–200 mM concentrations.

Stability data disclosed in the US patent application US20250041431A1 demonstrates a shelf life exceeding 24 months at 2–8°C, a critical commercial requirement. The European counterpart EP4538326A1 includes additional stability data for European climate zones and specifies viscosity parameters for compatibility with both auto-injector and pre-filled syringe delivery formats. The SC injection volume achievable with rHuPH20 co-formulation is 2–5 mL — a volume that would otherwise be impractical for SC delivery of a high-concentration antibody without enzymatic dispersion enhancement.

AstraZeneca’s layered IP strategy for SC Imfinzi

AstraZeneca has constructed a multi-layer patent estate around SC durvalumab, filing across at least three distinct IP layers: foundational formulation chemistry, SC-specific excipient and viscosity technology, and clinical method claims covering dosing regimens across multiple cancer indications. This architecture is designed to create durable protection that extends well beyond any single formulation patent.

The foundational layer is anchored by US11820819B2, a granted US patent on durvalumab formulation fundamentals covering the pH range 5.5–6.5, the histidine-based buffer system, polysorbate 80 concentration ranges, and sucrose as a lyoprotectant/cryoprotectant. This establishes baseline IP that any SC formulation must build upon. The second layer — the SC-specific technology — is represented by WO2024167823A1 (published August 2024), which covers viscosity-reducing excipient combinations including L-arginine and sodium chloride, high-concentration formulations above 100 mg/mL, and device-agnostic claims covering both auto-injector and pre-filled syringe delivery.

The third layer is the clinical methods estate. WO2023211973A1 (published November 2023) covers fixed-dose SC administration regimens — a shift from the weight-based IV dosing that characterises current Imfinzi labelling — across five cancer indications. Fixed dosing is standard for SC formulations and simplifies administration, but the method claims also serve a strategic purpose: they create a barrier for any competitor seeking to use an equivalent SC PD-L1 formulation in the same indications without licensing or designing around these claims.

Device integration is addressed through the US-specific claims in US20250041431A1, which include drug-device combination product specifications for auto-injector compatibility under the FDA’s 21 CFR Part 3 combination product pathway. The potential for patient self-administration — enabling home-based durvalumab maintenance therapy — is explicitly cited as a clinical development objective. According to published regulatory guidance reviewed in this dataset, ENHANZE-based SC products may qualify for a 505(b)(2) bridging pathway, which could accelerate the regulatory timeline by leveraging the established IV durvalumab safety and efficacy database.

“SC delivery enables administration in under 5 minutes versus a 60-minute IV infusion — a reduction of more than 90% in administration time that could fundamentally change the maintenance therapy experience for patients on the PACIFIC regimen.”

Halozyme ENHANZE: the enabling technology at the centre of SC checkpoint inhibitor development

Halozyme’s rHuPH20 ENHANZE platform is the critical enabling technology underpinning AstraZeneca’s SC durvalumab program — and, as the competitive landscape analysis reveals, the same platform being used by Merck, Roche, and Bristol-Myers Squibb. Understanding ENHANZE is therefore essential to understanding both the opportunity and the competitive dynamics of the SC checkpoint inhibitor market.

rHuPH20 works by temporarily degrading the hyaluronan matrix in the subcutaneous space. Hyaluronan is a high-molecular-weight polysaccharide that forms a dense, gel-like matrix in subcutaneous tissue, limiting the volume and concentration of biologics that can be absorbed. By enzymatically degrading this matrix, rHuPH20 increases subcutaneous tissue permeability 10–20 fold, enabling delivery of volumes up to 20 mL — far beyond the 1–2 mL limit of standard SC injection. The enzyme is active across a pH range of 5.5–8.0, which is compatible with standard antibody formulation buffers including the histidine system used in AstraZeneca’s SC durvalumab.

For SC bioavailability, the impact of rHuPH20 co-formulation is substantial. Without dispersion enhancement, large monoclonal antibodies typically achieve SC bioavailability of 60–80%. With rHuPH20, SC bioavailability for IgG1 antibodies rises to above 85%, according to pharmacokinetic reviews in this dataset. This is the threshold needed to demonstrate PK bioequivalence to IV administration in regulatory bridging studies — the core requirement for SC approval without full Phase III efficacy re-establishment.

The Halozyme royalty structure — approximately 1–3% of net sales — moderately impacts margin for AstraZeneca, but the commercial analysis in this dataset concludes that cost savings from IV-to-SC transition (reduced infusion centre resources, nursing time, and chair occupancy) more than offset the royalty burden. According to Halozyme, the ENHANZE platform has been licensed to more than 20 pharmaceutical partners, with more than 10 SC biologics now approved using the technology — a track record that provides AstraZeneca with a well-validated regulatory and commercial pathway.

Merck, Roche, and BMS: mapping the SC checkpoint inhibitor race

AstraZeneca is not developing SC durvalumab in isolation — three major competitors have filed SC checkpoint inhibitor patents using overlapping technology, and one (Roche) has already achieved regulatory approval. The competitive dynamics of this race are shaped by shared reliance on Halozyme ENHANZE, divergent clinical timelines, and the regulatory precedent established by SC atezolizumab.

Roche/Genentech: first-mover advantage with SC atezolizumab

Roche’s SC atezolizumab (Tecentriq SC, 1680 mg q4w) is the first approved SC anti-PD-L1 formulation, establishing the critical regulatory precedent for the class. The Phase III IMscin001 trial demonstrated PK bioequivalence with a geometric mean ratio of 1.06 (90% CI: 0.94–1.19) against IV atezolizumab (1200 mg q3w), with comparable objective response rates. SC formulation reduced administration time by more than 90% versus IV. EMA and FDA approvals were based on the PK bridging data combined with the IMscin001 dataset — a regulatory pathway that AstraZeneca is expected to follow for SC durvalumab. Roche’s US patent application US20230372484A1 uses a different viscosity-reduction approach to AstraZeneca’s: ionic excipients rather than L-arginine/NaCl combinations.

Merck: KEYNOTE-555 and the SC Keytruda threat

Merck’s SC pembrolizumab (Keytruda) program — covered by WO2024052882A1 (published March 2024) — uses Halozyme ENHANZE technology at a fixed dose of 400 mg q6w, aligned with the existing IV schedule. Phase I clinical data demonstrated PK bioequivalence to IV pembrolizumab with injection site reactions that were mild (Grade 1–2) in fewer than 15% of patients. The confirmatory Phase III KEYNOTE-555 trial is ongoing, with a potential approval timeline of 2025–2026. Given pembrolizumab’s dominant market position in checkpoint inhibitor therapy, a successful SC Keytruda approval would create substantial competitive pressure on AstraZeneca’s SC durvalumab program across overlapping indications including NSCLC. According to Merck, KEYNOTE-555 is actively enrolling.

Bristol-Myers Squibb: SC nivolumab and combination therapy complexity

Bristol-Myers Squibb’s SC nivolumab (Opdivo) program — covered by WO2022212815A1 (published October 2022) — targets a fixed dose of 900 mg q4w using hyaluronidase-based SC delivery. The BMS filing also raises the possibility of SC nivolumab combined with ipilimumab, which would represent a significant formulation and regulatory challenge given the need to co-administer two checkpoint inhibitors subcutaneously. As reported by FDA and the EMA, combination immunotherapy SC delivery remains an area of active regulatory development.

Commercial drivers, patient preference, and the lifecycle management imperative

The commercial rationale for SC durvalumab rests on three converging pressures: biosimilar IV competition, patient preference data that strongly favours SC administration, and payer incentives to reduce infusion centre costs. Together, these create a lifecycle management imperative that explains why AstraZeneca has accelerated its SC formulation program.

Biosimilar IV durvalumab entrants are projected for 2027–2030, according to the clinical evidence review in this dataset. A proprietary SC formulation with its own patent estate — covering composition, device compatibility, and clinical methods — creates a differentiated product that biosimilar manufacturers cannot replicate without independent development, regulatory approval, and potentially licensing of the Halozyme ENHANZE platform. This is the same lifecycle management strategy that has been successfully deployed by other manufacturers converting IV biologics to SC formulations.

Patient preference data is particularly compelling for durvalumab’s principal indication. The PACIFIC regimen — durvalumab maintenance therapy in unresectable Stage III NSCLC — involves repeated Q4W IV infusions over up to 12 months. Each 60-minute infusion requires clinic attendance, IV access, nursing supervision, and infusion chair occupancy. A systematic review of 18 clinical studies found that 72–89% of patients prefer SC administration over IV when efficacy is equivalent, with the primary drivers being reduced clinic time (average 45–60 minutes saved per visit), the ability for home administration, and reduced needle anxiety with auto-injectors. The preference was particularly strong in maintenance therapy settings — precisely the context in which durvalumab is most widely used.

SC checkpoint inhibitors are estimated to capture 40–60% of SC-eligible patients within five years of launch, according to the commercial landscape analysis reviewed in this dataset. For a drug with durvalumab’s patient volumes across NSCLC, SCLC, HCC, and BTC, this represents a substantial commercial opportunity. The payer dimension reinforces the case: infusion centre costs — including nursing time, chair time, pharmacy preparation, and facility overhead — are eliminated or substantially reduced with SC home administration, creating a health economics argument that is likely to support formulary positioning of SC durvalumab over IV alternatives in cost-sensitive healthcare systems.

“SC checkpoint inhibitors are estimated to capture 40–60% of SC-eligible patients within five years of launch — a commercial shift that makes AstraZeneca’s SC durvalumab program not just a formulation exercise, but a strategic imperative.”

The regulatory pathway is increasingly well-defined. Roche’s IMscin001 trial demonstrated that PK bioequivalence — demonstrated by a geometric mean ratio of 1.06 with a 90% confidence interval of 0.94–1.19 — is sufficient for SC checkpoint inhibitor approval when combined with a robust PK bridging study. AstraZeneca’s Phase I/II PK bridging study for SC durvalumab follows this template, and the ENHANZE-based 505(b)(2) bridging pathway identified in the regulatory literature reviewed here could further compress the development timeline. According to guidance published by EMA and the FDA, PK bridging with demonstrated bioequivalence is the accepted standard for route-of-administration switches for approved biologics. The WIPO patent database confirms the breadth of AstraZeneca’s international filing strategy across this program.